---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-22-000025"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:03:27.980598+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences receives FDA IND clearance for CB-011, allogeneic anti-BCMA CAR-T therapy for multiple myeloma

## Summary
- CB-011 is a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking.
- CaMMouflage Phase 1 trial is an open-label, multicenter study evaluating CB-011 in relapsed/refractory multiple myeloma.
- Patient enrollment at dose level 1 (50x10^6 CAR-T cells) expected to begin in early 2023.
- CB-011 uses Cas12a chRDNA edits: anti-BCMA CAR insertion, TRAC KO, and B2M-HLA-E fusion for immune cloaking.
- This is Caribou's second allogeneic CAR-T to enter clinic, following CB-010 (anti-CD19, PD-1 KO) in ANTLER trial.

## SEC filing metadata
- accession: 0001619856-22-000025
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000025/0001619856-22-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000025/crbu-20221121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-22-000025
- JSON: https://secwatch.observer/filing/0001619856-22-000025.json
- Plain text: https://secwatch.observer/filing/0001619856-22-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.